Cargando…

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis

BACKGROUND: Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have been found to significantly improve patient outcomes, including reduced hospitalizations and emergency room (ER) admissions and increased medication adherence among adult patients with schizophrenia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Dee, Thompson-Leduc, Philippe, Ghelerter, Isabelle, Nguyen, Ha, Lafeuille, Marie-Hélène, Benson, Carmela, Mavros, Panagiotis, Lefebvre, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144083/ https://www.ncbi.nlm.nih.gov/pubmed/33909272 http://dx.doi.org/10.1007/s40263-021-00815-y

Ejemplares similares

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies
por: Correll, Christoph U., et al.
Publicado: (2023)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia
por: Lin, Dee, et al.
Publicado: (2023)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
por: Keenan, Alexander, et al.
Publicado: (2022)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: ATRASH, Shebli, et al.
Publicado: (2021)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Atrash, Shebli, et al.
Publicado: (2021)

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2013)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
por: Baeza, Inmaculada, et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
por: Kaplan, Gabriel, et al.
Publicado: (2013)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
por: Vanderpoel, Julie, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia
por: Basu, Anirban, et al.
Publicado: (2023)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
por: Viala, Annie, et al.
Publicado: (2012)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tnef17eqd2d40ha47datn43bst